TDCS to Improve Post-Stroke Cognitive Impairment
Launched by JOHNS HOPKINS UNIVERSITY · Jan 4, 2022
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether a treatment called transcranial direct current stimulation (tDCS) can help improve thinking and memory skills in patients who have had a minor stroke and are experiencing mild cognitive impairment. The study will involve about 60 participants who will be randomly assigned to receive either the tDCS treatment along with computerized cognitive therapy or a fake version of the treatment (called sham) with the same therapy. Researchers will assess how well participants are doing before and after the treatment using tests that evaluate their cognitive abilities, while also using advanced imaging techniques to look at brain activity over several months.
To be eligible for this study, participants should be adults over 18 years old who have experienced a recent minor stroke, confirmed by an MRI scan. They should not have a history of serious neurological issues or certain other medical conditions that could interfere with the study. Participants will need to visit the University of Maryland for treatment and follow-up sessions, where they can expect to undergo cognitive assessments and brain imaging to track their progress. This trial is currently recruiting participants, and it aims to find out if tDCS can be a beneficial treatment for improving cognitive function after a stroke.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults (≥18 years) presenting with neurological symptoms due to acute ischemic stroke (symptom onset within the week prior to admission).
- • 2. Evidence on brain MRI of acute ischemic stroke (imaging negative strokes and TIAs will be excluded).
- • 3. Native English speaker (by self-report) prior to stroke.
- • 4. NIHSS \<8 at initial follow-up visit (approximately 30 days post-stroke).
- • 5. mRS 0-2 at initial follow-up visit.
- Exclusion Criteria:
- • 1. Primary intracerebral hemorrhage- as evidenced by blood on head CT or MRI.
- • 2. Presence of proximal large vessel occlusion.
- • 3. Cortical exam findings including aphasia or neglect.
- • 4. Prior report or history of dementia or undertreated psychiatric illness.
- • 5. Uncorrected hearing or visual loss.
- • 6. Inability to attend treatment or follow-up sessions.
- • 7. Inability to travel to College Park (UMD) for MEG recording sessions.
- • 8. Presence of any of the following that would lead to significant artifact on MEG: cardiac pacemaker, intracranial clips, metal implants or external clips within 10mm of the head, metal implants in the eyes (unlikely given that all patients will have an MRI and criteria are similar).
- • 9. Claustrophobia, obesity, and/or any other reason leading to difficulty staying in the MEG machine for up to 1 hour.
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Elisabeth B Marsh, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials